Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Sarah Turner is an associate in the corporate practice group in the London office.
Ms. Turner advises both private and public companies on a wide range of matters, including mergers and acquisitions, private financings, general corporate governance and capital market transactions, acting for both corporate issuers and financial institutions in relation to IPO’s and equity offerings on the Main and AIM markets of the LSE. She has particular expertise in advising on transactions in the life sciences and technology industries.
- Represented the management team of The Foundry in relation to HgCapital’s investment under the terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD). The Foundry is a leading provider of award-winning creative software.
- Acted for Cenkos Securities plc as sole co-ordinator and bookrunner to the AA Group plc on its £1,385 billion IPO on the London Main Market.
- Advised Consort Medical plc, listed on the London Main Market, in relation to its £98.9 million rights issue in connection with its £230 million acquisition of Aesica Holdco Limited.
- Acted for Horizon Discovery Group plc:
- on its IPO and admission to the AIM market of the London Stock Exchange, raising approximately £40 million before expenses for Horizon and a further £28.6 million for selling shareholders; and
- on its placing and sale of existing shares to raise £25 million before expenses for Horizon and a further £15 million for selling shareholders.
- Advised Vectura Group Plc, a product development company listed on the London Main Market, on its acquisition of German pharmaceutical company Activaero GmbH for a total consideration of €130 million (£108 million) and related £52 million fundraising.
- Advised Lombard Medical, Inc. on its Scheme of Arrangement and $55 million U.S. initial public offering and the listing of the company’s ordinary shares on the NASDAQ Global Market.
- Acted for Charles Stanley Securities, as NOMAD, and WG Partners as financial adviser and broker to Venture Life Group plc, on its IPO and admission to AIM.
- Represented Rightster Group plc, a global online video distribution and monetisation network on its IPO and admission to AIM and associated fundraising of approximately £20 million.
- Advised AstraZeneca and MedImmune, its global biologics research and development arm, on the acquisition of Spirogen, a privately-held biotechnology company focused on antibody-drug conjugate technology for use in oncology.
- Advised Canaccord Genuity Limited as nominated adviser and joint broker to AIM-quoted Lombard Medical Technologies plc on a £21 million placing of ordinary shares.
- Advised ReNeuron Group plc, an AIM listed stem cell therapy company, on its £33 million fundraising.
- Represented Oxford Biomedica plc, listed on the London Main Market, on its 2010 placing and open offer to raise approximately £20 million and its 2012 firm placing and open offer to raise up to £16 million.
- Acted for a US multinational pharmaceutical company on the integration of a major acquisition in over 60 countries.
July 13, 2015
LONDON, 13 July, 2015 — Covington is advising AIM-listed ReNeuron Group plc, a leading clinical stage stem cell therapy company, on its latest follow-on financing announced on 10 July. ReNeuron is raising £68.4 million by way of an institutional placing of new shares arranged by Cenkos Securities plc. The placing is conditional on the receipt of certain ...
May 13, 2015
LONDON, May 13, 2015 — Covington has advised AIM-listed Horizon Discovery Group plc on a £40.1 million accelerated bookbuild placing announced on May 1, 2015. The financing is being undertaken to raise £25 million in new money for the company through a primary offering and £15.1 million for certain shareholders through a sale of their existing shares. The ...
Covington Advises Consort Medical on Aesica Holdco Acquisition and related £260 million financing
October 10, 2014
LONDON, 10 October, 2014 — Covington & Burling is advising Consort Medical plc on the acquisition of Aesica Holdco Limited and its operating subsidiaries from private equity fund Silverfleet Capital and its management shareholders for a total consideration of approximately £230 million. Covington is also advising Consort Medical plc on the £98.9 million Rights ...
July 10, 2014
LONDON, 10 July, 2014 — Rightster Group plc, an AIM-listed cloud-based global video distribution and monetisation network, announced the acquisition of Viral Management Limited, the proposed acquisition of Base79 Limited and the placing of new shares by Cenkos to raise £42 million for the company. Covington & Burling advised Rightster on these transactions, ...
July 10, 2014
LONDON, 2 June, 2014 — Oxford BioMedica plc, a Main Market listed gene based biopharmaceutical company, announced that it intends to raise gross proceeds of up to £25.7 million through a fundraising by means of a placing and subscriptions and an open offer. Covington & Burling advised the company on the transaction. The proceeds of the fundraising will be used ...
May 1, 2014
LONDON, 1 May, 2014 — Covington & Burling advised Lombard Medical, Inc. on its $55 million U.S. initial public offering and the listing of the company’s ordinary shares on the NASDAQ Global Market. Covington also advised the company on its change of domicile from the U.K. to the Cayman Islands and the delisting of its shares from the AIM market of the London ...
April 7, 2014, The Lawyer
Covington's Paul Claydon, Guy Dingley, and Sarah Hoult are mentioned regarding their representation of Horizon Discovery on their IPO.
Covington Advises Horizon Discovery on AIM IPO
March 31, 2014
LONDON, 31 March, 2014 — Horizon Discovery Group plc announced the admission of its shares to the AIM market of the London Stock Exchange. Covington & Burling advised Horizon on the transaction. The IPO raised approximately £40 million before expenses for Horizon and a further £28.6 million for selling shareholders, which puts a market capitalisation on the ...
Covington Advises Charles Stanley Securities and WG Partners on the Admission to AIM of Venture Life Group plc
March 28, 2014
LONDON, 28 March, 2014 — Covington & Burling advised Charles Stanley Securities acting as nominated adviser and WG Partners acting as financial adviser and broker to Venture Life Group plc, the international consumer healthcare company, on its admission to AIM. On admission to AIM, Venture Life will complete the acquisition of Biokosmes Srl, an Italian company ...
March 25, 2014
LONDON, 25 March, 2014 — Covington & Burling advised Vectura Group Plc, a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases, on its acquisition of German pharmaceutical company Activaero GmbH for a total consideration of €130 million (£108 million) and related fundraising to ...
Covington Advises Rightster on AIM IPO
November 12, 2013
LONDON, 12 November, 2013 — Rightster Group plc., a global provider of cloud-based services that optimise the distribution and monetisation of live and on-demand video, today announced the admission of its shares to the AIM market of the London Stock Exchange. Covington & Burling advised Rightster on the transaction. Rightster has raised £20.4 million before ...
July 22, 2013
LONDON, 22 July, 2013 — Covington & Burling acted for AIM listed stem cell therapy company, ReNeuron Group plc, on its £33 million fund raising. ReNeuron today announced that £25.35 million (before expenses) will be raised through an oversubscribed placing of new shares to fund the company’s therapeutic programmes through Phase II trials, together with a £7.8 ...
Covington Advises Canaccord Genuity Ltd and WG Partners on Lombard Medical Fundraising
June 20, 2013
LONDON, 20 June, 2013 — Covington & Burling acted for Canaccord Genuity Limited (nominated adviser and joint broker) and WG Partners, a trading name of Charles Stanley & Co. Ltd (joint broker), to AIM-quoted Lombard Medical Technologies plc on its placing and subscription of ordinary shares to raise approximately £22 million before expenses. Lombard is a ...
Covington Advises WH Ireland Thalassa Holdings Placing
April 18, 2013
LONDON, 18 April, 2013 — Covington & Burling LLP acted for WH Ireland, nominated adviser and broker to Thalassa Holdings Ltd, on a £5.4 million placing of ordinary shares for Thalassa Holdings. Thalassa Holdings Ltd, incorporated and registered in the British Virgin Islands and quoted on AIM, is a holding company with a focus on marine seismic operations. The ...
Covington Advises Armani on New Franchise Agreement
April 25, 2012
LONDON, 25 April, 2012 — Covington & Burling advised Giorgio Armani in a deal to terminate its existing joint venture and store lease arrangement in India with DLF Retail Brands. As a result of the termination, Armani will enter into a new franchise arrangement with Genesis Luxury Fashion Pvt. Ltd. Under the terms of the agreement, all assets of DLF Retail ...
- Legal 500 UK, Flotations: Small & Mid-cap (2016)